DE69132048T2 - Verwendung von Steroiden zur Inhibierung von Angiogenesis - Google Patents

Verwendung von Steroiden zur Inhibierung von Angiogenesis

Info

Publication number
DE69132048T2
DE69132048T2 DE69132048T DE69132048T DE69132048T2 DE 69132048 T2 DE69132048 T2 DE 69132048T2 DE 69132048 T DE69132048 T DE 69132048T DE 69132048 T DE69132048 T DE 69132048T DE 69132048 T2 DE69132048 T2 DE 69132048T2
Authority
DE
Germany
Prior art keywords
steroids
inhibit angiogenesis
useful
angiogenesis
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69132048T
Other languages
English (en)
Other versions
DE69132048D1 (de
Inventor
William Wilks
Frank Dekoning
Adrian Aristoff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Vision LLC
Original Assignee
Alcon Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Laboratories Inc filed Critical Alcon Laboratories Inc
Application granted granted Critical
Publication of DE69132048D1 publication Critical patent/DE69132048D1/de
Publication of DE69132048T2 publication Critical patent/DE69132048T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes
    • C07J71/0015—Oxiranes at position 9(11)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C07J3/005—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0053—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0061—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16
    • C07J5/0069—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group
    • C07J5/0076—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group by an alkyl group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • C07J7/0085—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by an halogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69132048T 1990-06-11 1991-05-23 Verwendung von Steroiden zur Inhibierung von Angiogenesis Expired - Fee Related DE69132048T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US53689490A 1990-06-11 1990-06-11
US60966190A 1990-11-06 1990-11-06
PCT/US1991/003459 WO1991019731A1 (en) 1990-06-11 1991-05-23 Steroids which inhibit angiogenesis

Publications (2)

Publication Number Publication Date
DE69132048D1 DE69132048D1 (de) 2000-04-20
DE69132048T2 true DE69132048T2 (de) 2000-07-13

Family

ID=27065303

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69132048T Expired - Fee Related DE69132048T2 (de) 1990-06-11 1991-05-23 Verwendung von Steroiden zur Inhibierung von Angiogenesis

Country Status (11)

Country Link
EP (1) EP0533703B1 (de)
JP (1) JPH05507912A (de)
AT (1) ATE190623T1 (de)
AU (1) AU657690B2 (de)
CA (1) CA2081205C (de)
DE (1) DE69132048T2 (de)
DK (1) DK0533703T3 (de)
ES (1) ES2143978T3 (de)
GR (1) GR3033524T3 (de)
HK (1) HK1013078A1 (de)
WO (1) WO1991019731A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5990099A (en) * 1988-10-31 1999-11-23 Alcon Laboratories, Inc. Angiostatic agents and methods and compositions for controlling ocular hypertension
EP1236470A3 (de) * 1991-11-22 2004-09-01 Alcon Laboratories, Inc. Angiostatische Steroide
US5770592A (en) * 1991-11-22 1998-06-23 Alcon Laboratories, Inc. Prevention and treatment of ocular neovascularization using angiostatic steroids
FR2701262B1 (fr) * 1993-02-05 1995-03-24 Roussel Uclaf Nouveau procédé de préparation de stéroïdes 6 alpa, 9 alpha-difluorés et nouveaus intermédiaires.
DK0688333T3 (da) * 1993-03-10 1999-02-08 Magainin Pharma Steroidderivater, farmaceutiske præparater indeholdende disse og deres anvendelse som antibiotika eller desinfektionsmidler
US5856535A (en) * 1994-08-18 1999-01-05 Magainin Pharmaceuticals, Inc. Aminosterol ester compounds
US5840740A (en) * 1995-06-07 1998-11-24 Magainin Pharmaceuticals Inc. Aminosterol compounds and a method of treating infection using the aminosterol compounds
US5994336A (en) * 1995-06-07 1999-11-30 Magainin Pharmaceuticals Inc. Method of inhibiting proliferation of cells by administering an aminosterol compound
US5847172A (en) * 1995-06-07 1998-12-08 Magainin Pharmaceuticals Inc. Certain aminosterol compounds and pharmaceutical compositions including these compounds
US5792635A (en) * 1995-06-07 1998-08-11 Magainin Pharmaceuticals, Inc. Method of inhibiting the sodium/proton exchanger NHE3 and method of inhibiting growth by administering squalamine
US5840936A (en) * 1995-06-07 1998-11-24 Magainin Pharmaceuticals Inc. Aminosterol compounds useful as inhibitors of the sodium/proton exchanger (NHE)
US5795885A (en) * 1995-06-07 1998-08-18 Magainin Pharmaceuticals Inc. Method of inhibiting profileration of cells by administering an aminosterol compound
US6143738A (en) * 1995-06-07 2000-11-07 Magainin Pharmaceuticals, Inc. Therapeutic uses for an aminosterol compound
US5874597A (en) * 1995-06-07 1999-02-23 Magainin Pharmaceuticals, Inc. Certain aminosterol compounds and pharmaceutical compositions including these compounds
US5763430A (en) * 1995-06-07 1998-06-09 Magainin Pharmaceuticals Inc. Method of treating a viral infection by administering a steroid compound
US6596712B2 (en) 1996-04-26 2003-07-22 Genaera Corporation Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities
WO1997040835A1 (en) * 1996-04-26 1997-11-06 Magainin Pharmaceuticals Inc. Treatment of carcinomas using squalamine in combination with other anti-cancer agents
AU3968597A (en) 1996-08-02 1998-02-25 Children's Medical Center Corporation Method of regulating the female reproductive system through angiogenesis inhibitors
US6262283B1 (en) 1996-12-06 2001-07-17 Magainin Pharmaceuticals Inc. Stereoselective synthesis of 24-hydroxylated compounds useful for the preparation of aminosterols, vitamin D analogs, and other compounds
US6596703B1 (en) 1997-07-11 2003-07-22 Jagotec Ag Promotion of wound healing utilizing steroids having reduced deteriorous systemic side effects typical of glucocorticoids, mineralocorticoids and sex steroids
AU5687199A (en) * 1998-08-24 2000-03-14 Global Vascular Concepts, Inc. Use of anti-angiogenic agents for inhibiting vessel wall injury
PT1274718E (pt) 2000-04-12 2007-01-31 Genaera Corp Processo para a preparação de esteróis 7. alfa-hidroxi 3- aminosubstítuidos utilizando intermediários com um grupo 7. alfa-hidroxilo desprotegido
US7595055B2 (en) 2003-01-29 2009-09-29 Dal-Hoon Son Pharmaceutical composition comprising an extract or compounds isolated from Elfvingia applanata for the prevention and the treatment of diabetes and diabetic complications
WO2004112772A1 (en) * 2003-06-13 2004-12-29 Alcon, Inc. Formulations of non-steroidal anti-inflammatory agents to treat pathologic ocular angiogenesis
PT1919290E (pt) 2005-07-12 2014-03-20 Ampio Pharmaceuticals Inc Métodos e produtos para tratamento de doenças
LT2805720T (lt) 2008-05-28 2019-09-25 Reveragen Biopharma, Inc. Nehormoniniai steroidiniai nf-kb moduliatoriai, skirti ligoms gydyti
DE202010017530U1 (de) 2009-06-22 2012-03-28 Dmi Acquisition Corp. Danazolverbindung zur Behandlung von Krankheiten
US9198921B2 (en) 2010-04-05 2015-12-01 Reveragen Biopharma, Inc. Non-hormonal steroid modulators of NF-κB for treatment of disease
SG10201705044YA (en) 2012-12-19 2017-07-28 Ampio Pharmaceuticals Inc Method for treatment of diseases
US10799514B2 (en) 2015-06-29 2020-10-13 Reveragen Biopharma, Inc. Non-hormonal steroid modulators of NF-kappa beta for treatment of disease
US11382922B2 (en) 2019-03-07 2022-07-12 Reveragen Biopharma, Inc. Aqueous oral pharmaceutical suspension compositions

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3067194A (en) * 1961-12-01 1962-12-04 Merck & Co Inc 4, 6-pregnadieno-[3, 2-c] pyrazoles and processes of preparing them
US3067193A (en) * 1961-12-01 1962-12-04 Merck & Co Inc 4-pregneno-[3, 2-c] pyrazoles and processes of preparing them
US3300483A (en) * 1961-12-01 1967-01-24 Merck & Co Inc 4, 6-pregnadieno-[3, 2-c] pyrazoles and processes of preparing them
US3158601A (en) * 1962-10-26 1964-11-24 Merck & Co Inc 5alpha-pregneno-[3, 2-c] pyrazoles and process of preparing them
US4041055A (en) * 1975-11-17 1977-08-09 The Upjohn Company Process for the preparation of 17α-hydroxyprogesterones and corticoids from androstenes
DE3315324A1 (de) * 1983-04-25 1984-10-31 Schering AG, 1000 Berlin und 4709 Bergkamen Verfahren zur herstellung von 17(alpha)-(br oder j)-ethinyl-17ss-or-steroiden
CA1310009C (en) * 1984-03-28 1992-11-10 John Mark Braughler Ester prodrugs of steroids
US4613463A (en) * 1984-11-01 1986-09-23 The Upjohn Company Process and intermediates for the preparation of 17 alphahydroxyprogesterones and corticoids from an enol steroid
WO1987001706A2 (en) * 1985-09-12 1987-03-26 The Upjohn Company C20 through c26 amino steroids
WO1987002672A1 (en) * 1985-10-23 1987-05-07 The Upjohn Company Tetrahydro angiostatic steroids
US4771042A (en) * 1985-11-25 1988-09-13 The Upjohn Company Inhibition of angiogenesis involving the coadministration of steroids with heparin or heparin fragments
CA1317283C (en) * 1986-11-05 1993-05-04 Douglas Alan Livingston Steroidal 17–-silyl ethers and process to corticoids and progesterones
AU5640390A (en) * 1989-06-16 1991-01-08 Upjohn Company, The Suramin type compounds and angiostatic steroids to inhibit angiogenesis

Also Published As

Publication number Publication date
DK0533703T3 (da) 2000-08-14
AU7984891A (en) 1992-01-07
EP0533703B1 (de) 2000-03-15
WO1991019731A1 (en) 1991-12-26
CA2081205C (en) 2001-02-27
EP0533703A1 (de) 1993-03-31
AU657690B2 (en) 1995-03-23
HK1013078A1 (en) 1999-08-13
ATE190623T1 (de) 2000-04-15
ES2143978T3 (es) 2000-06-01
CA2081205A1 (en) 1991-12-12
GR3033524T3 (en) 2000-09-29
DE69132048D1 (de) 2000-04-20
JPH05507912A (ja) 1993-11-11

Similar Documents

Publication Publication Date Title
ATE190623T1 (de) Verwendung von steroiden zur inhibierung von angiogenesis
HK56897A (en) Benzocyclobutyl-or indanyl-alkyl-amino-alkyl substituted 3-benzazepin-2-ones useful in the treatment of cardiovascular diseases
JPS5756480A (en) Novel substituted pyradinyl-1,2,4- oxadiazol-5-one and manufacture
DK0668769T3 (da) Egebarkekstrakt-relaterede syntetiske sammensætninger og fremgangsmåde til deres anvendelse
ATE76294T1 (de) Galanthamin oder dessen analoge zur behandlung der alzheimerschen krankheit.
AU1808488A (en) Compounds for the treatment of alzheimer's disease
FI971420A (fi) Menetelmä diabetes mellituksen hoitamiseksi KGF:ää käyttämällä
GR1000118B (el) Συνθεσις 1,2-διοξετανων & ενδιαμεσαι ουσιαι δι αυτην.
BG102250A (en) The use of marigold-extracted glycosides for the treatment of psoriasis
DE69130497D1 (de) Neue Verwendung von 1-Alpha-hydroxylierten-19-nor-vitamin-D-Verbindungen zur Behandlung von Psoriasis
NO984950L (no) Forbindelser med veksthormonfrigj°rende egenskaper
ZA886097B (en) Pharmaceutical composition for the treatment of psoriasis
MD960168A (ro) Metodă şi compuşi pentru tratamentul infecţiilor virale
DE2966673D1 (en) Pharmaceutical composition useful for the treatment of hypercholesteremia
ZA929879B (en) Compositions for the treatment of mammalian diseases.
DE68928752D1 (de) Zubereitungen zur verwendung bei der behandlung von psoriasis und von neuropsychiatrischen krankheiten
DE3879709T2 (de) Platin-arzneimittel.
RO86562A2 (ro) Compozitie vegetala medicamentoasa pentru tratarea unor afectiuni hepato-biliare
GR3004272T3 (de)
RO86650B1 (ro) Preparat farmaceutic pentru tratarea dermatozelor
DE69117566T2 (de) Verwendung von Isomonoolen zur Behandlung und Prophylaxe von Krebserkrankungen
JPS56154456A (en) S-alkyl-3-alkylthiopropionothioates, nanufacture and medicine
ES2112562T3 (es) Nuevo difenilhexeno.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee